How Quickly Does Wegovy Suppress Appetite?
Wegovy (semaglutide) starts suppressing appetite within hours of the first dose. Clinical data show peak appetite-reducing effects around 1-2 days after subcutaneous injection, driven by its activation of GLP-1 receptors in the brain's hunger centers. Patients often report feeling fuller sooner on eating, with effects building over the first week as steady-state blood levels form.[1][2]
What Do Patients Notice in the First Week?
In STEP trials, about 70% of participants experienced reduced hunger by day 3-5, with average daily calorie intake dropping 20-30% by week 1. This varies by dose—starting at 0.25 mg weekly ramps slowly to minimize nausea, delaying full appetite control to week 4-5 at 1-2.4 mg doses. Early responders feel it in 24-48 hours; others take up to 7 days.[1][3]
How Long Until Maximum Appetite Suppression?
Full effects peak at 4-8 weeks, once therapeutic levels stabilize. Long-term data from SUSTAIN trials (similar semaglutide formulations) confirm sustained suppression for 68+ weeks, with 15-20% average weight loss tied to ongoing appetite control. Missing doses can rebound hunger within days.[2][4]
Factors Affecting Onset Speed
- Dose and titration: Lower starter doses (0.25-0.5 mg) act slower than maintenance (2.4 mg).
- Individual response: Faster in those with higher BMI or insulin resistance; slower if gastrointestinal side effects dominate early.
- Timing with food: Effects strongest 4-6 hours post-injection, lasting a week.
- Lifestyle: Pairing with low-calorie diet amplifies perceived suppression immediately.[3][5]
Common Early Side Effects Tied to Appetite Changes
Nausea hits 44% in week 1, often mistaken for or enhancing appetite loss. This fades by week 4 for most, unmasking true hunger reduction. Diarrhea or vomiting can delay noticing benefits.[1][4]
How Wegovy Compares to Ozempic or Mounjaro for Appetite Control
Wegovy (2.4 mg weekly) matches Ozempic's (up to 2 mg) onset but sustains stronger suppression due to higher dosing. Mounjaro (tirzepatide) acts faster—appetite drop in 1 day for many—via dual GLP-1/GIP action, though head-to-head trials show similar week-4 results.[2][6]
[1] Novo Nordisk Wegovy Prescribing Information, FDA label (2023).
[2] Wilding JP et al., NEJM (STEP 1 trial, 2021).
[3] Rubino DM et al., JAMA (STEP 5 trial, 2021).
[4] Garvey WT et al., JAMA (SUSTAIN 6, adapted for semaglutide, 2018).
[5] DrugPatentWatch.com, semaglutide pharmacokinetics profile. Link
[6] Jastreboff AM et al., NEJM (SURMOUNT-1 for tirzepatide, 2022).